Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
Ended Cooperative Agreement Awarded Last action
- Award ID
- R41CA200161
- Recipient
-
Adecto Pharmaceuticals, Inc. UEI DAR5SR7BVBB6
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $374,292
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Boston, MA 02111, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$39,198 | |
| Amendment | -$3,000 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $3,000 | |
| Amendment | $0 | |
| Amendment | $50,000 | |
| Amendment | $63,490 | |
| Original award | $300,000 |
Show all 11
Quick answers
Who received award R41CA200161?
R41CA200161 was awarded to Adecto Pharmaceuticals, Inc. by National Cancer Institute (National Institutes of Health) on April 15, 2016.
How much is award R41CA200161 worth?
$374,292 has been obligated on R41CA200161.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award